Select your country »

Practice Guidelines
Supporting practitioners through education



Practice Guidelines provide practitioners with detailed information on complex conditions, and suggested evidence-based interventions for use in practice.

 
 

 

HealthEase Insights NAFLD Insert

Date: 2018-01-16
Author: BioCeuticals
Description: Non-alcoholic fatty liver disease (NAFLD), encompassing both non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), is the most common cause of liver disease in Australia. There is increasing evidence for considering NAFLD as part of metabolic syndrome including obesity, hyperinsulinaemia, insulin resistance, hypertriglyceridaemia and hypertension. Obesity is a clear risk factor for developing this common condition. The conventional therapeutic approach to NAFLD is based on lifestyle intervention, but there is no consensus on the ideal pharmacological treatment.

More Details

 
Chat online with our team now
Close

Patient support

If you are a patient or consumer, please contact your healthcare practitioner or pharmacist for advice, or find your nearest practitioner here.

Practitioner support

Log me In